RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 123 filers reported holding RHYTHM PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 2.18 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,890,594 | -0.3% | 105,975 | +62.7% | 0.01% | +14.3% |
| Q4 2022 | $1,896,819 | +33.5% | 65,138 | +12.3% | 0.01% | 0.0% |
| Q3 2022 | $1,421,000 | +676.5% | 57,994 | +31.3% | 0.01% | +600.0% |
| Q2 2022 | $183,000 | +8.9% | 44,164 | +203.3% | 0.00% | 0.0% |
| Q1 2022 | $168,000 | -58.4% | 14,562 | -29.3% | 0.00% | -50.0% |
| Q2 2021 | $404,000 | -73.5% | 20,611 | -71.2% | 0.00% | -77.8% |
| Q1 2021 | $1,522,000 | +1.7% | 71,544 | +42.1% | 0.01% | -18.2% |
| Q4 2020 | $1,497,000 | +574.3% | 50,341 | +391.7% | 0.01% | +266.7% |
| Q3 2020 | $222,000 | -73.2% | 10,239 | -71.6% | 0.00% | -40.0% |
| Q4 2019 | $828,000 | +70.4% | 36,077 | +60.2% | 0.01% | +25.0% |
| Q3 2019 | $486,000 | -31.6% | 22,515 | -13.2% | 0.00% | -50.0% |
| Q1 2019 | $711,000 | -15.6% | 25,945 | -17.2% | 0.01% | -20.0% |
| Q4 2018 | $842,000 | -11.9% | 31,337 | -4.4% | 0.01% | -9.1% |
| Q3 2018 | $956,000 | +60.9% | 32,763 | +72.5% | 0.01% | +37.5% |
| Q2 2018 | $594,000 | – | 18,993 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 2,075,000 | $47,569,375 | 5.56% |
| NEA Management Company, LLC | 2,909,956 | $66,710,741 | 5.15% |
| Opaleye Management Inc. | 653,000 | $14,970,025 | 4.87% |
| Frazier Life Sciences Management, L.P. | 2,371,304 | $54,362,144 | 3.61% |
| VR Adviser, LLC | 1,090,000 | $24,988,250 | 2.63% |
| RA Capital Management | 5,676,067 | $130,123,836 | 2.56% |
| Samsara BioCapital, LLC | 345,293 | $7,915,842 | 2.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 260,537 | $5,972,811 | 1.81% |
| Logos Global Management LP | 400,000 | $9,170,000 | 1.22% |
| Cormorant Asset Management, LP | 850,000 | $19,486,250 | 1.14% |